Pipeline

Products		Clinical indication	Region								Licensee
Ripasudil hydrochloride hydrate	GLANATEC®	Glaucoma and ocular hypertension	Japan, Asia *							●	Kowa
	K-321	Fuchs endothelial corneal dystrophy	US, etc.				●				Kowa
Ripasudil hydrochloride hydrate/ Brimonidine tartrate	GLA-ALPHA®	Glaucoma and ocular hypertension	Japan							●	Kowa
DW-1002		ILM staining	Europe, US, etc.							●	DORC
		ILM staining	Japan				●				Wakamoto Pharmaceutical
		ALC staining	Japan				●
		ILM, ERM and PVR membrane staining	Europe, etc.							●	DORC
		ILM staining and ERM staining	US				●				DORC
DW-1001		Ophthalmic treatment agent	Japan		●						ROHTO Pharmaceutical
H-1337		Glaucoma and ocular hypertension	US			●					Developed internally
DW-5LBT		Neuropathic pain after shingles	US					●			Jointly developed with MEDRx
DWR-2206		Bullous Keratopathy	Japan			●					Jointly developed with ActualEyes

*For Japan, the period for receiving royalty income ended in September 2024. For Asia, royalty income is received in certain areas.

The Group is engaged in the discovery of new drug candidate compounds with a focus on protein kinase inhibitors. There are various diseases in which protein kinases are relevant, but we are promoting research with a focus on ophthalmic conditions in particular.
Leveraging our drug discovery platform technology, we are actively promoting alliances with other companies.

Our main project consists of the development of signal transmission inhibitors at our research institute (in the research facilities of Mie University) for treatment of ophthalmic, neuropathic, and respiratory conditions. In terms of joint development, we are forging ahead with multiple initiatives, such as a targeted protein degradation project with UBiENCE Inc., and an ophthalmic condition drug discovery project with RaQualia Pharma Inc..